PDF) WTX101 in patients newly diagnosed with Wilson disease: final
Por um escritor misterioso
Descrição
Table 4 from EASL Clinical Practice Guidelines: Wilson's disease.
Copper(I)-binding properties of de-coppering drugs for the treatment of Wilson disease. α-Lipoic acid as a potential anti-copper agent
Updates on Wilson disease : Clinical Liver Disease
Update on the Diagnosis and Management of Wilson Disease
Full article: Metabolic disposition of WTX101 (bis-choline tetrathiomolybdate) in a rat model of Wilson disease
PDF) Ammonium tetrathiomolybdate in the decoppering phase treatment of Wilson's disease with neurological symptoms: A case series
IJMS, Free Full-Text
Bis-choline tetrathiomolybdate prevents copper-induced blood–brain barrier damage
PDF) WTX101 in patients newly diagnosed with Wilson disease: final results of a global, prospective phase 2 trial
Copper(I)-binding properties of de-coppering drugs for the treatment of Wilson disease. α-Lipoic acid as a potential anti-copper agent
Full article: Metabolic disposition of WTX101 (bis-choline tetrathiomolybdate) in a rat model of Wilson disease
Exploring the potential of trientine tetrahydrochloride in the treatment of Wilson disease - ScienceDirect
Chelation therapy in liver diseases of childhood: Current status and response
Copper depletion modulates mitochondrial oxidative phosphorylation to impair triple negative breast cancer metastasis
Diagnosis - Wilson Disease Association
de
por adulto (o preço varia de acordo com o tamanho do grupo)
